

# Swedencare AB (publ) has completed the acquisition of av Summit Veterinary Pharmaceuticals Limited which was made public on March 24th, 2025, and carries out an issue of shares to the seller

**Swedencare AB (publ) has today, April 1<sup>st</sup> 2025, gained access to the business of Summit Veterinary Pharmaceuticals Limited ("Summit"), which was acquired on March 24th, 2025. Summit develops, produces, and sells Animal Health Specials exclusively for veterinary professionals in the UK and Hong Kong. With this strategic acquisition, Swedencare has boosted its presence in the rapidly growing Animal Health Specials market. The initial purchase price is GBP 30 million (approximately SEK 395.4 million). The cash consideration will include GBP 27 million (approximately SEK 355.9 million, drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare, approximately GBP 3 million (approximately SEK 39.5 million). A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1st, 2027.**

The board of directors for the company has, with the support of the authorization from the annual general meeting on April 25th, 2024, resolved on the issue of 978,119 shares to the seller of Summit. The reason for the issue is to make payment to the seller in accordance with the share purchase agreement. The subscription price in the issue was determined, in accordance with the share purchase agreement, at SEK 40.60 per share, which corresponds to the volume-weighted average price of the company's share on the Nasdaq First North Growth Market during 20 trading days immediately preceding the date before the date of signing the agreement. The board therefore assesses that the subscription price is made on market terms. The new issue entails a dilution of approximately 0.61 percent based on the total number of shares and votes in the company after the issue. Total number of shares after completed transaction amounts to 159,840,958.

For more information about the acquired business, please see press release from March 24th, 2025, when the acquisition was made public on the Company homepage [www.swedencare.com](http://www.swedencare.com).

---

**For more information, please contact:**

---

Håkan Lagerberg, CEO Swedencare  
Phone: +46 (0)73 517 01 70  
Email: [hakan.lagerberg@swedencare.se](mailto:hakan.lagerberg@swedencare.se)

Jenny Graflind, CFO Swedencare  
Phone: +46 (0)73 944 85 54  
Email: [jenny.graflind@swedencare.se](mailto:jenny.graflind@swedencare.se)

FNCA is the Certified Adviser of the Company

Please visit the Company homepage [www.swedencare.com](http://www.swedencare.com)

---

**About Swedencare**

---

Swedencare is listed on the NASDAQ First North Growth Market and also trades on the OTCQX® Best Market. We develop, produce, and sell premium products in the global and rapidly growing pet healthcare market, focusing on cats, dogs, and horses. Our extensive product portfolio includes strong brands such as **NaturVet®**, **Innovet**, **Pet MD®**, **Rx Vitamins®**, **nutravet®**, **Rileys®**, and **ProDen PlaqueOff®**, the original solution for good oral health.

With headquarters in Malmö, our products are sold in approximately 70 countries through veterinarians, pet stores, and online. Our extensive distribution network consists of subsidiaries in nine countries, along with an international network of retailers. Swedencare has experienced strong growth for several years while maintaining high profitability.

*This information is information that Swedencare is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-01 13:45 CEST.*

---

**Attachments**

---

Swedencare AB (publ) has completed the acquisition of av Summit Veterinary Pharmaceuticals Limited which was made public on March 24th, 2025, and carries out an issue of shares to the seller